Drug Profile
Research programme: obesity therapeutics - PhysioGenix
Alternative Names: 3-BMAPLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator PhysioGenix
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA
- 07 Dec 2005 Preclinical trials in Obesity in USA (unspecified route)